Liflex Science, Inc. is a new drug R&D company founded based on Professor Jin-Hong Kim's(Seoul National University) 20-year, KRW 10 billion-plus investment in osteoarthritis and its treatment, We aim to develop a global, first-in-class ASO injection treatment capable of fundamentally restoring osteoarthritis, a treatment previously limited to pain/inflammation treatments. We are currently in preclinical testing after confirming the substance. (1) Self-selection of the cause of osteoarthritis problem (microRNA-204) (2) Development of platform technology for decomposing the corresponding mircoRNA and development of decomposing substance/ASO and completion of patent application (3) PD/PK/Tox experiments in progress and verification completed in our own research institute (4) Currently in non-clinical stage. We are focusing on R&D by securing a total of 5 billion won in external investment/projects.

We aim to develop an oligonucleotide cartilage regeneration injection targeting miR-204, a key factor in the development of degenerative arthritis. Specifically, we have identified a target pathogenic factor that not only prevents disease progression but also induces cartilage regeneration. Furthermore, we have identified a substance that effectively inhibits this pathogenic factor and are conducting efficacy and toxicity testing.